GGHC
MRSN

Gilder Gagnon Howe & Co’s Mersana Therapeutics MRSN Stock Holding History

Gilder Gagnon Howe & Co’s Portfolio MRSN Stock Details MRSN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-200
Closed -$70K – 298
2017
Q2 		$70K Buy
+200
New +$69.2K ﹤0.01% 273

Other funds holding MRSN

NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return
PAI
ProQuest Associates IV Naples, Florida $53M AUM 3.35% 1-Year Est. Return
RCP
Rho Capital Partners New York $20.4M AUM
ACH
ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Gilder Gagnon Howe & Co's MRSN Position: Q3 2017 in Review

Gilder Gagnon Howe & Co sold out of Mersana Therapeutics (MRSN) in Q3 2017, closing a stake of 200 shares — an estimated $70K sold.

Gilder Gagnon Howe & Co first reported a position in MRSN in Q2 2017 and held it in 1 quarter. The position peaked at $70K in Q2 2017. 42 funds tracked by Wall St. Rank hold MRSN as of Q3 2017.

  • Gilder Gagnon Howe & Co reported no remaining Mersana Therapeutics position as of Q3 2017 after selling out during the quarter.
  • Gilder Gagnon Howe & Co sold 200 Mersana Therapeutics shares in Q3 2017, an estimated $70K.
  • Gilder Gagnon Howe & Co first reported a position in Mersana Therapeutics in Q2 2017 and held it in 1 quarter.
  • Gilder Gagnon Howe & Co's Mersana Therapeutics position peaked at $70K in Q2 2017.
  • 42 funds tracked by Wall St. Rank held Mersana Therapeutics as of Q3 2017.

Based on Gilder Gagnon Howe & Co's 13F filing for Q3 2017, filed 6 Nov 2017.